Literature DB >> 31014518

Systemic therapy in cervical cancer: 30 years in review.

Michalis Liontos1, Anastasios Kyriazoglou2, Ioannis Dimitriadis2, Meletios-Athanasios Dimopoulos2, Aristotelis Bamias2.   

Abstract

Advanced-inoperable cervical cancer is a challenging entity due to increased percentage of locoregional and distant recurrences. Furthermore, recurrent cervical cancer not amenable to radical treatment as well as de novo metastatic disease are considered incurable with dismal prognosis. Well-designed clinical trials conducted during the last 30 years have revealed the active chemotherapeutic agents as well as their optimal combinations. The rational approach that has led to the current treatment algorithms as well as the introduction of targeted therapies based on the knowledge of the molecular pathogenesis of the disease are discussed in this review.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Chemotherapy; Immunotherapy; Targeted therapy

Mesh:

Year:  2019        PMID: 31014518     DOI: 10.1016/j.critrevonc.2019.02.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  32 in total

1.  SEOM clinical guidelines for cervical cancer (2019).

Authors:  A de Juan; A Redondo; M J Rubio; Y García; J Cueva; L Gaba; A Yubero; J Alarcón; C Maximiano; A Oaknin
Journal:  Clin Transl Oncol       Date:  2020-01-24       Impact factor: 3.405

2.  Identification and Experimental Validation of Immune-Associate lncRNAs for Predicting Prognosis in Cervical Cancer.

Authors:  Jing Ye; Xiaojing Chen; Weiguo Lu
Journal:  Onco Targets Ther       Date:  2021-09-07       Impact factor: 4.147

3.  Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.

Authors:  Hui Yao; Xiya Jiang; Hengtao Fu; Yinting Yang; Qinqin Jin; Weiyu Zhang; Wujun Cao; Wei Gao; Senlin Wang; Yuting Zhu; Jie Ying; Lu Tian; Guo Chen; Zhuting Tong; Jian Qi; Shuguang Zhou
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

4.  Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer.

Authors:  Rongjia Su; Chengwen Jin; Hualei Bu; Jiangdong Xiang; Lina Zhou; Chengjuan Jin
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

Review 5.  Immuno-Oncology for Gynecologic Malignancies.

Authors:  Jeffrey A How; Ami Patel; Amir A Jazaeri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

6.  Analysis of related risk factors of lung metastasis after laparoscopic radical hysterectomy of cervical cancer.

Authors:  Liu Henglian; Wang Jiajun; Wang Caixia; Lu Gang; Xia Min
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 7.  Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer.

Authors:  Elvin Peter Chizenga; Heidi Abrahamse
Journal:  Pharmaceutics       Date:  2021-04-28       Impact factor: 6.321

8.  ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway.

Authors:  Tao Jiang; Bing Zhou; Yuan Meng Li; Qui Ying Yang; Kai Jia Tu; Long Yu Li
Journal:  Oncol Lett       Date:  2020-05-19       Impact factor: 2.967

9.  CircRNA circ-ATAD1 Is Upregulated in Cervical Squamous Cell Carcinoma and Regulates Cell Proliferation and Apoptosis by Suppressing the Maturation of miR-218.

Authors:  Zhiyi Fei; Li Qin; Fang Luo; Yi Yu
Journal:  Reprod Sci       Date:  2021-07-12       Impact factor: 3.060

10.  Laparoscopic Radical Hysterectomy Results in Higher Recurrence Rate Versus Open Abdominal Surgery for Stage IB1 Cervical Cancer Patients With Tumor Size Less Than 2 Centimeter: A Retrospective Propensity Score-Matched Study.

Authors:  Xiaoyue Chen; Jiangtao Yu; Hongqin Zhao; Yan Hu; Haiyan Zhu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.